title: [Management of wheezing disorders in infants participating in the PARIS birth cohort].
abstract: BACKGROUND
  While wheezing disorders are common in preschool children, their management is not well defined. The aim of this study was to assess the use of medical health care resources due to wheezing disorders in infants aged 18 months followed up in the Pollution and Asthma Risk: an Infant Study (PARIS) birth cohort.
  
  
  METHODS
  Data on wheezing disorders, medical visits and medication on account of respiratory disorders during the previous 12 months were collected with a standardized questionnaire, administered by a paediatrician, during the health check offered to every child aged 18 months included in the PARIS birth cohort.
  
  
  RESULTS
  The prevalence of wheezing disorders during the past 12 months amounted to 560/1974 (28.4%). Among wheezers, 493 (89.3%) required a medical visit because of difficult breathing; 61 (11.0%) went to the emergency room, 35 (6.4%) were admitted to the hospital and 375 (67.2%) received an inhaled anti-asthmatic medication. Recourse to chest physiotherapy was reported in 472 of them (85.1%).
  
  
  CONCLUSIONS
  This study confirms the high use of healthcare resources because of wheezing disorders in infants and suggests a higher use of anti-asthmatic medications in France compared to other European countries.
authors.affiliation: EA 4064, laboratoire santé publique et environnement, faculté des sciences pharmaceutiques et biologiques, université Paris Descartes, 4, avenue de l'Observatoire, 75006 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Herr
authors.forename: L
authors.initials: L
authors.lastname: Nikasinovic
authors.forename: C
authors.initials: C
authors.lastname: Foucault
authors.forename: A M
authors.initials: AM
authors.lastname: Le Marec
authors.forename: J P
authors.initials: JP
authors.lastname: Giordanella
authors.forename: J
authors.initials: J
authors.lastname: Just
authors.forename: I
authors.initials: I
authors.lastname: Momas
mesh_terms: D000280:Administration, Inhalation; D000397:Air Pollution / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage; D001249:Asthma / Q000150:complications / Q000453:epidemiology / Q000209:etiology; D015331:Cohort Studies; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D010297:Paris / Q000453:epidemiology; D036801:Parturition; D015995:Prevalence; D012135:Respiratory Sounds / Q000503:physiopathology; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D018927:Anti-Asthmatic Agents